Insulin-Sensitizing Agent and Butyrate-Producing Bacterium Combination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin-sensitizing agents have limited therapeutic effect and require high doses, leading to adverse events, and there is a need for new strategies to enhance insulin sensitivity and treat metabolic diseases such as insulin resistance and related conditions.
Innovation Solution
Combining an insulin-sensitizing agent with a butyrate-producing bacterium, such as Anaerobutyricum soehngenii or Intestinimonas butyriciproducens, to enhance insulin sensitivity and treat metabolic diseases like type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of insulin-sensitizing agents are used to improve therapeutic effect, then insulin sensitivity improves, but adverse events increase
Solution Approach 1:
The patent combines insulin-sensitizing agents with butyrate-producing bacteria (such as Anaerobutyricum soehngenii or Intestinimonas butyriciproducens) to create a synergistic therapeutic effect. This combination allows for enhanced insulin sensitivity at lower doses of the insulin-sensitizing agent, thereby reducing adverse events while maintaining or improving therapeutic effectiveness.
2Reliability
If high doses of insulin-sensitizing agents are used to treat metabolic diseases, then disease treatment efficacy improves, but the need for high doses indicates limited therapeutic effect and requires new strategies
Solution Approach 1:
The patent merges insulin-sensitizing agents with butyrate-producing bacteria to achieve enhanced therapeutic effects at lower doses. The butyrate-producing bacteria contribute to improved insulin sensitivity through butyrate production, which works synergistically with the insulin-sensitizing agent, thereby reducing the quantity of the agent required while maintaining disease treatment efficacy.
3Ease of operation
If conventional insulin-sensitizing agents are used alone, then treatment is simple, but therapeutic effect remains limited and adverse events occur
Solution Approach 1:
The patent combines insulin-sensitizing agents with butyrate-producing bacteria to overcome the limited therapeutic effect of conventional monotherapy. This combination approach enhances insulin sensitivity more effectively than either agent alone, while the synergistic interaction allows for reduced dosing and fewer adverse events, maintaining reasonable treatment simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of insulin-sensitizing agents with butyrate-producing bacteria shows a synergistic therapeutic effect, improving insulin sensitivity and reducing insulin resistance-related conditions, potentially reducing the need for high doses and adverse events.
Implementation Method 1
a butyrate-producing bacterium, more preferably chosen from Anaerobutyricum soehngenii or Intestinimonas butyriciproducens
Data Source
AI summary
This disclosure is concerned with a combination comprising at least one butyrate-producing bacterium and at least one insulin-sensitizing agent for use in the prevention and/or treatment of metabolic disease, insulin resistance and insulin resistance-related conditions, preferably chosen from type 1 diabetes mellitus, type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, insulin resistance in endocrine disease, Polycystic Ovary Syndrome (PCOS), Nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). The insulin-sensitizing agent and the butyrate-producing bacterium, at least in part, have a synergistic effect on lowering insulin resistance in subjects.